The Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) of the Germans Trias i Pujol Research Institute (IGTP) has renewed for the third consecutive time its certificate of compliance with Good Laboratory Practices (GLP) in accordance with Directive 2004/9/EC.

This certificate, awarded by the Department of Health of the Government of Catalonia, in accordance with the principles established by the Spanish Royal Decree 822/1993, certifies that the centre complies with the quality standards required to conduct preclinical studies for the evaluation of medical devices' efficacy, biocompatibility and tolerance. The accreditation guarantees that the data generated in the validation processes of medical devices developed at CMCiB are reliable, reproducible, auditable, and recognised by regulatory authorities and scientific institutions at the international level.

Good Laboratory Practices (GLP) principles are quality systems regarding the organisational processes and the conditions under non-clinical health and environmental safety studies are planned, carried out, controlled, registered, archived and reported. These studies are required for the registration and authorisation of chemical products intended for human and veterinary use, including medicines, cosmetics, healthcare products, pesticides, phytosanitary products, food additives for human and animal consumption, and industrial chemicals. Since 2021, GLP certification has been a legal requirement to carry out the preclinical validation of medical devices as a prior step to clinical trials and their eventual commercialisation.

The CMCiB obtained this accreditation for the first time in 2022, with a first renewal in 2024, and has renewed it again in February 2026. This third reaccreditation consolidates the centre as a key reference in the translation of scientific knowledge into clinical practice and the industrial sector, reflected by its commitment to maintaining the highest quality standards.

The renewal has been made possible thanks to the team of professionals at CMCiB, responsible for directing the studies and ensuring the quality of processes, together with the external support provided in training and advisory services by the Quality Assurance Unit of FalcoQuality. The inspection included an evaluation of the facilities, operational procedures and implemented quality controls, ensuring compliance with the current legal framework. Sara Capdevila, technical director of the CMCiB highlights that "each audit is increasingly demanding, and this result is the product of teamwork that reaffirms our commitment to continuous improvement and to consolidating the centre as a reference in the validation of medical devices, ensuring that health innovations progress safely towards human use".

This certification reaffirms the centre's commitment to quality, scientific rigour, and continuous improvement, and strengthens its strategic role in advancing translational medicine. The recognition validates the excellence of its processes and results, and reinforces the confidence of researchers, companies, and regulatory authorities in its capacity to produce solid and reliable evidence that advances innovation and healthcare.